ProCE Banner Activity

PROTAC ER Degraders in ER+/HER2- MBC After ET: Novel ER-Targeting Therapy Data and a Look to the Future 

Slideset

Download these slides to gain expert insights on the current clinical trial research investigating novel PROTAC ER degrader agents for patients with ER+/HER2- MBC after disease progression on endocrine therapy. 

Released: November 19, 2024

Expiration: November 18, 2025

Share

Faculty

Erika P. Hamilton

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Chair, Breast Executive Committee
Sarah Cannon Research Institute
Nashville, Tennessee

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.